Dienogest was synthesized in 1979 in Jena , Germany under the leadership of Prof. Kurt Ponsold, was initially referred to as STS-557 .   It was found that its potency was 10 times that of levonorgestrel .  The first product on the market to contain dienogest was a combined oral contraceptive pill (with ethinylestradiol), Valette , introduced in 1995 and made by Jenapharm .  In 2007, dienogest was introduced as Dinagest in Japan for the treatment of endometriosis, and it was subsequently marketed for this indication as Visanne in Europe and Australia in December 2009 and April 2010, respectively.  Qlaira was introduced in Europe in 2009 and Natazia was introduced in the United States in 2010. 
However, in December 2004 the United States the 14-member Food and Drug Administration (FDA) advisory committee, plus voting consultants, for Reproductive Health Drugs unanimously rejected Procter and Gamble's fast-track request for Intrinsa citing concerns about off-label use . In Canada, post-menopausal women have been able to obtain government-approved testosterone treatment since 2002. In Australia, post-menopausal women can use Organon testosterone implants which have to be surgically inserted and last from three to six months.